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Abstract 
Increasing access to direct-acting antiviral (DAA)-treatment for hepatitis C virus (HCV) 
infection and decelerating the rise in high-risk behaviour over the next decade, could curb the 
HCV epidemic among HIV-positive men-who-have-sex-with-men (MSM). We investigated 
if similar outcomes would be achieved by short-term intensive interventions like the Swiss-
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HCVree-trial. We used a HCV-transmission model emulating two 12-months intensive-
interventions combining risk-counselling with 1) universal DAA-treatment (pangenotypic 
intervention) and 2) DAA-treatment for HCV-genotypes 1 and 4 (replicating the Swiss-
HCVree-trial). To capture potential changes outside intensive-interventions, we varied time 
from HCV-infection to treatment in clinical-routine and overall high-risk behaviour among 
HIV-positive MSM. Simulated prevalence dropped from 5.5% in 2016 to ≤2.0% over the 
intervention period (June/2016-May/2017) with the pangenotypic-intervention, and to ≤3.6% 
with the Swiss-HCVree-trial. Assuming time to treatment in clinical-routine reflected 
reimbursement restrictions (METAVIR ≥F2, 16.9 years) and stable high-risk behaviour in the 
overall MSM population, prevalence in 2025 reached 13.1% without intensive intervention, 
11.1% with the pangenotypic intervention and 11.8% with the Swiss-HCVree-trial. If time to 
treatment in clinical-routine was 2 years, prevalence in 2025 declined to 4.8% without 
intensive-intervention, to 2.8% with the pangenotypic intervention, and to 3.5% with the 
Swiss-HCVree-trial. In this scenario, the pangenotypic intervention and the Swiss-HCVree-
trial reduced cumulative (2016-2025) treatment episodes by 36% and 24% respectively. 
Therefore, intensive interventions could reduce future HCV-treatment costs and boost the 
benefits of long-term efforts to prevent high-risk behaviour and to reduce treatment delay. But 
if after intensive interventions treatment is deferred until F2, short-term benefits of intensive 
interventions would dissipate in the long-term. 
 
Key words: Men who have sex with men; Hepatitis C virus; HIV; Direct-acting antivirals; 
treatment as prevention. 
 
Abbreviations: HCV, hepatitis C virus; MSM, men who have sex with men; DAA, direct-
acting antivirals 
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INTRODUCTION 
Hepatitis C virus (HCV) is increasingly transmitted among HIV-positive men who have sex 
with men (MSM), engage in high-risk sexual practices and do not identify themselves as 
intravenous drug users(1-6).  
We and others have shown that reductions in high-risk practices associated with HCV 
transmission combined with widespread use of direct-acting antivirals (DAA)-based HCV 
treatment could reduce HCV-incidence and prevalence (7, 8). In some countries including 
Switzerland, universal HCV treatment for HIV-positive MSM is not possible because DAA-
based HCV treatment is only reimbursed for patients who reached METAVIR stage F2 or in 
rare instances, in patients with clear extrahepatic manifestations of HCV disease.  
An intensive, short-term intervention (referred to as intensive intervention) that prevents 
transmission through risk counseling and provides early DAA-based HCV treatment, could 
help combat the HCV epidemic among HIV-positive MSM. An intervention of this type is 
ongoing in the Swiss HIV Cohort Study (SHCS) (9): the Swiss-HCVree-trial 
(NCT02785666). The primary outcomes of this trial are safety and efficacy of the study 
drugs. Active HCV testing preceded this trial and all patients infected with replicating HCV 
genotypes 1 or 4 were offered treatment and risk counseling. To what extent intensive 
interventions like the Swiss-HCVree-trial can influence the epidemic is however uncertain. 
In this modeling study, we assessed the potential to interrupt HCV transmission among HCV-
positive MSM of the Swiss-HCVree-trial and a similar intensive intervention where all HCV 
genotypes could be treated. This hypothetical intervention will be referred to as pangenotypic-
intervention and aims to provide more generalizable estimates of the potential of such 
interventions. We projected HCV prevalence, incidence, genotype distribution and cumulative 
number of treatment episodes without and with such intensive interventions. Projections 
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assumed different scenarios outside intensive interventions. These scenarios included a range 
of treatment rates in the clinical-routine reflecting regulatory drug restrictions as well as 
different trends in high-risk behaviour in the overall HIV-positive MSM population. 
 
MATERIALS AND METHODS 
The Swiss-HCVree-trial 
The Swiss-HCVree-trial is a phase III, multi-center, open-label trial taking place between June 
2016 and May 2017 in the SHCS. In preparation for the trial, intensified HCV-PCR based 
testing of all MSM participating in the cohort took place between October 2015 and May 
2016. All patients infected with replicating HCV genotypes 1 or 4 were offered treatment 
with the study drugs grazoprevir/elbasvir ±ribavirin. The study drugs were prescribed from 
June 2016 to February 2017 independently of reimbursement restrictions. The Swiss-HCVree-
trial was restricted to HCV genotypes 1 or 4 because grazoprevir/elbasvir is not sufficiently 
active against HCV genotypes 2 and 3 [which account for 12% of all infections (10)]. In 
addition to HCV treatment, enrolled patients who reported inconsistent condom use with 
occasional partners (a marker for high-risk behaviour) and provided their consent to a 
behavioural intervention received 45-minute sessions of individual risk counseling at weeks 4, 
6, 8, and 12. 
 
Mathematical model of an intensive intervention 
To simulate the effect of intensive interventions, we extended a previously developed model 
of HCV transmission among HIV-positive MSM in Switzerland(7). The model uses a system 
of ordinary differential equations where the population is classified into 24 compartments 
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defined by i) stage of HCV infection (uninfected, infected, and on treatment); ii) HCV 
genotype (1or 4 and 2 or 3); iii) risk behaviour (with and without high-risk practices 
associated with HCV transmission); iv) enrolment in HIV-care; and v) enrolment in the 
intensive intervention. The model assumes that a fraction of patients reporting condomless 
anal sex with occasional partners also engage in practices associated with HCV transmission. 
Model parameters are described in Table 1 and Supplementary Table S1.  
Figure 1 qualitatively depicts the redistribution of the population upon introduction and 
completion of an intensive intervention.  
Model parameterization was fully based on estimates previous to the start of the Swiss-
HCVree-trial. 
 
Rules inside the intensive interventions 
Rules in common between the pangenotypic intervention and the Swiss-HCVree-trial. 
 The model matches the testing period of the Swiss-HCVree-trial. Enrolled individuals are 
treated with DAAs for 12 weeks. Because high-risk behaviour is likely to be underreported 
(11), and risk counselling is not 100% effective (12), the model assumed that intensified risk 
counselling within the intensive interventions had an effectiveness of 50% i.e., risk 
counselling led to 50% of patients with high-risk behaviour at enrolment in the intensive 
interventions to permanently stop this behaviour. Of note, individuals are assumed to become 
susceptible to reinfection after HCV clearance regardless of ongoing intensive interventions. 
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Differences between the pangenotypic intervention and the Swiss-HCVree-trial.  
HCV-test and treatment took place in HIV-positive MSM enrolled in HIV-care for 
simulations with the pangenotypic intervention and in those enrolled in the SHCS for 
simulations with the Swiss-HCVree-trial. Of note, we estimated that the SHCS included 84% 
of all HIV-positive MSM in Switzerland (13) (14). Patients enrolled in the pangenotypic 
intervention infected with all genotypes were treated within 3 months since the beginning of 
the intervention. Analogously, in the Swiss-HCVree-trial patients infected with genotypes 1 
or 4 were treated within 9 months from the beginning of the trial. 
We modeled the following scenarios for patients not enrolled in intensive interventions and 
for everyone after the completion of the intervention: 
 
Scenarios outside intensive interventions 
Treatment in clinical-routine. We assumed HCV treatment outside intensive interventions or 
in absence of intensive interventions (Figure 1) to be DAA-based resulting in 95% sustained 
virological response (SVR) (15). Treatment rates were chosen to reflect the (mean) time from 
HCV infection to treatment start corresponding to four different scenarios of clinical-routine: 
i) mean time from HCV infection to F2 in the METAVIR scale (16.9 years, labeled F2 
scenario) (16), reflecting the current reimbursement restriction in Switzerland and other 
countries); ii) mean time from HCV infection to F1 in the METAVIR scale [8.2 years, labeled 
F1 scenario)] (16); iii) 2 years; and iv)1 year.  
High-risk behavior in the overall (HIV-positive MSM) population. We considered two main 
scenarios where the fraction of individuals engaging in high-risk practices associated with 
HCV transmission: 1) remained stable at the value estimated for 2016 (14%, labeled stable 
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high-risk behaviour) or 2) declined continuously to reach a 50% reduction by 2025 (labeled 
reduced high-risk behaviour).  
 
Projections on the effect of intensive interventions  
The overall projection period was 2016-2025. Based on the scenarios depicted above, we 
reported trajectories, short-term (end-of-intervention, i.e., May 2017) and long-term (2025) 
HCV prevalence, incidence, genotype distribution and cumulative number of treatment 
episodes.  
We undertook independent analyses that assumed i) no intensive intervention; ii) the 
pangenotypic intervention; and iii) the Swiss-HCVree-trial. We only projected genotype 
distribution with the Swiss-HCVree-trial (since treatment is subtype-independent in i and ii). 
All these projections correspond to HIV-positive MSM living in Switzerland, including those 
who are not enrolled in HIV-care. 
Projections with the Swiss-HCVree-trial restricted to SHCS participants. To allow validation 
of these results with SHCS data in the future, we also reported separate model projections 
with the Swiss-HCVree-trial restricted to the subset of modeled individuals enrolled in the 
SHCS.  
 
Sensitivity analyses 
We undertook three sensitivity analyses for MSM enrolled in the SHCS. These analyses 
assumed: I) further increase in high-risk behaviour in the overall population; II) larger 
fraction of HCV infections acquired by contacts outside the modeled population; and III) 
higher efficacy of risk counseling interventions within the Swiss-HCVree-trial. 
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Table 1 describes the model parameters associated with all scenarios including sensitivity 
analyses.  
 
RESULTS 
At the beginning of the screening period 4,257 MSM were enrolled in the SHCS. Simulated 
HCV prevalence and incidence at the beginning of the trial were 5.8% and 2.6 per 100 
person-years respectively. Further characteristics of the modelled population are described in 
detail in (7, 10). 
Projections on the effect of the pangenotypic intervention 
End-of-intervention projections (Figure 2). Without intensive intervention, assuming stable 
risk behaviour and under the current reimbursement restrictions (F2 scenario), simulated HCV 
prevalence increased from 5.6% (in June 2016) to 7.7% in mid-2017. But by the end of the 
pangenotypic intervention (May 2017), simulated prevalence had declined to <2.0% across all 
scenarios of treatment rate in clinical-routine and high-risk behaviour in the overall 
population. Of note, if time from HCV infection to treatment in the overall population was <2 
years, by May 2017, the model also predicted a decline in prevalence even without intensive 
intervention. Little differences between the two scenarios of high-risk behaviour in the overall 
population were observed in these short-term simulations. 
Long-term projections (2025)(Figure 3A). If we assumed stable high-risk behaviour in the 
overall population, expected prevalence in 2025 without intensive interventions ranged from 
13.1% to 0.7% across scenarios of treatment rate in clinical-routine. The long-term effect of 
the pangenotypic intervention was smaller than that at the end of the intervention. This 
occurred because after the intervention period, HCV-prevalence increased again. The speed of 
this increase was determined by treatment rate in clinical-routine and high-risk behaviour in 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
the overall population. These variables also influenced the absolute reduction in long-term 
prevalence following the pangenotypic intervention, which ranged between 0.1 and 2.0 
percent points. If high-risk behavior in the overall population remained stable and treatment in 
clinical-routine was deferred according to the current reimbursement restriction (F2 scenario), 
simulated HCV-prevalence in 2025 exceeded that in 2016 by at least 5 percent points with or 
without intensive interventions. But if time from HCV infection to treatment in clinical-
routine was < 2 years, simulated prevalence in 2025 was lower than that in 2016. If time from 
HCV infection to treatment in clinical-routine was 2 years, the pangenotypic intervention 
reduced expected prevalence by 41% (from 4.8% without pangenotypic intervention to 2.8%) 
and 42% (from 1.6% to 0.9%) when assuming stable and reduced high-risk behaviour in the 
overall population respectively. 
When time from HCV infection to treatment in clinical-routine was one year, HCV-
prevalence dropped to <0.7%. 
 
Cumulative number of treatment episodes (2016-2025)(Figure 3B). In the F2 scenario, the 
pangenotypic intervention increased the cumulative number of treatment episodes by 35% 
(from 214 to 288) when assuming stable high-risk behaviour in the overall population (Figure 
3B). But with much shorter time from HCV infection to treatment in clinical-routine, the 
pangenotypic intervention was predicted to reduce treatment episodes with respect to no 
intensive intervention . For instance, if time from HCV infection to treatment in clinical-
routine was 2 years and high-risk behaviour in the overall population stable, the pangenotypic 
intervention reduced the cumulative number of treatment episodes by 36% (from 678 to 431).  
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Projections on the effect of the Swiss-HCVree-trial 
Model projections with the pangenotypic intervention and those with the Swiss-HCVree-trial 
were close (Supplementary Figures S1 and S2). However, as expected, the Swiss-HCVree-
trial was less effective at reducing HCV-prevalence and treatment episodes than the 
pangenotypic intervention . These results are reported in detail in the Supplementary Material. 
In all scenarios, reduced high-risk behaviour in the overall population was more successful 
than either the pangenotypic intervention or the Swiss-HCVree-trial at reducing HCV-
prevalence in the long-term (Figure 3 and Supplementary Figure S2A).  
 
Expected trajectories of HCV-prevalence, -incidence and genotype distribution with the 
Swiss-HCVree-trial 
Figure 4 and Supplementary Figure S3 display simulated HCV-prevalence, genotype 
distribution and incidence over the projection period without intensive intervention and with 
the Swiss-HCVree-trial. Here we set time from HCV infection to treatment in clinical-routine 
to reflect the F2 scenario and to 2 years. These figures illustrate the trajectories towards the 
time points reported in Figures 2, 3A and Supplementary Figures S1 and S2A.  
If we combined stable high-risk behaviour in the overall population with the F2 scenario 
(Figure 4A and Supplementary Figure S3A), prevalence and incidence dropped to <3.6% 
and <1.3/100 person-years (from an incidence of 2.4 person-years in 2016) respectively over 
the intervention period. But prevalence and incidence rose again when the intervention ended. 
However, if mean time from HCV infection to treatment in clinical-routine was 2 years, 
prevalence and incidence dropped and remained low even after the completion of the trial 
(Figure 4A and Supplementary Figure S3A). 
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Reduced high-risk behaviour in the overall population led to similar outcomes (Figure 4B and 
Supplementary Figure S3B). But as expected, the post-intervention speeds of increase in 
prevalence and incidence were much lower in this case. 
In the F2 scenario, simulated incidence with the Swiss-HCVree-trial surpassed that without 
intensive intervention in mid-2019 and remained slightly above until the end of the projection 
period (Supplementary Figure S3).  
Because only patients infected with genotypes 1 or 4 are enrolled in the Swiss-HCVree-trial, a 
comparative advantage for the spread of genotypes 2 and 3 is imminent. Figures 4C and 4D 
show the projected genotype distribution when assuming stable and reduced high-risk 
behaviour in the overall population.  
In the F2 scenario, the proportion of infections with genotypes 2 or 3 increased from 11% in 
2016 to up to 27% in 2025. Earlier HCV treatment in clinical-routine led to smaller changes 
in genotype distribution (Figures 4C and 4D). This occurs because treatment in clinical-
routine is homogeneous across genotypes. Early treatment therefore shirks the discrepancy 
between genotypes imposed by the Swiss HCV trial. 
Projections with the Swiss-HCVree-trial restricted to SHCS participants: Supplementary 
Figures S4 to S7 show model projections for MSM enrolled in SHCS. As expected, these 
results were very close to those obtained in the main analyses (Figures 2 to 4 and 
Supplementary Figures S1 to S3).  
Supplementary Table S2 summarizes key simulation outcomes. 
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Sensitivity analyses 
The outcomes of the sensitivity analyses are reported in the supplementary material. The 
projected effects of the Swiss-HCVree-trial remained qualitatively unchanged (Supplementary 
Figures S4 to S7). 
 
DISCUSSION 
Principal findings 
Our results suggest that intensive interventions can reduce HCV prevalence among HIV-
positive MSM. Simulated prevalence dropped below 2.0% (from 5.5% in 2016) over the 
intervention period with the pangenotypic intervention and below 3.6% with the Swiss-
HCVree-trial. But prevalence would only remain low after intensive interventions if 
reimbursement limitations (METAVIR>F2) are retracted so that treatment outside intensive 
interventions can start much earlier after HCV diagnosis. Reductions in prevalence by year 
2025 due to intensive interventions ranged between 10% and 41%. Intensive interventions 
also reduced the projected number of treatment episodes when time from HCV infection to 
treatment was <2 years. If we assumed stable high-risk behaviour in the overall population, 
the percentage of averted treatment episodes reached 36% and 24% with the pangenotypic 
intervention and with the Swiss-HCVree-trial respectively. 
If time from HCV infection to treatment in the clinical-routine was reduced to < 2 years, 
prevalence would decrease steadily even without intensive interventions. When time from 
HCV infection to treatment in clinical-routine was 1 year, the estimated effect of intensive 
interventions was negligible. This occurs because treatment rate in clinical-routine and within 
the intensive intervention are very similar in this case. This high treatment rates result in basic 
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reproduction numbers smaller than 1 independently of intensive interventions. Prevalence and 
incidence in this situation are therefore low (<0.7% and < 0.4/100py respectively in 2025).  
High costs of DAA remain a major barrier to treatment. A recent study estimated prices of 
DAA therapy adjusted for purchasing power parity raging between 1,861 USD and 154,227 
USD (17). Independently of intensive interventions, reducing time from HCV infection to 
treatment in the clinical-routine to 1 year would at most double the cumulative number of 
treatment episodes between 2016 and 2025 while decreasing prevalence by at least a factor of 
18 over the same period. In particular, reducing time from HCV infection to treatment in 
clinical-routine from the scenario F2 to 1 year, combined with an intensive intervention would 
only increase the number of treatments by 20% by 2025. Therefore, more aggressive 
treatment and the relief of reimbursement restrictions could substantially reduce HCV 
transmission at relatively low additional costs in the long-term. The model also suggests that 
if treatment reimbursement restrictions remain (METAVIR >F2), the Swiss-HCVree-trial 
would increase by at least 33% the cumulative number of treatments between 2016 and 2025 
in Switzerland. 
A sensitivity analysis where we increased the effectiveness of risk counselling within the 
Swiss-HCVree-trial resulted in a modest reduction in long-term prevalence (<0.54 percent 
points by 2025). By contrast, sustained reductions in high-risk behaviour in the overall 
population, could rapidly curb the epidemic even without increasing access to treatment. This 
underscores the importance of sustained efforts to prevent exposure to HCV transmission. But 
long-lasting reductions in high-risk behaviour are hard to achieve in HIV-positive MSM on 
antitretroviral therapy (12). This implies the need for treatment as prevention to accompany 
behavioural interventions. For instance, if stabilization of high risk-behaviour is achieved, 
earlier treatment initiation could substantially reduce HCV prevalence.  
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Strengths and limitations 
To our knowledge this is the first published study to use a mathematical model to project the 
population level impact of a clinical trial or other intensive interventions to tackle HCV 
transmission. The strengths and limitations of the core model have been discussed elsewhere 
(7). We believe the main strength of the mathematical model developed in the present study is 
that it emulates the dynamics of sexually transmitted HCV and its response to real-life 
interventions and to hypothetical scenarios of treatment and high-risk behaviour 
simultaneously. Moreover, our results could be generalized to other settings as regulatory 
drug restrictions remain in several countries (18-20) and we provide estimates independent of 
the particular design of the Swiss-HCVree-trial by modelling the pangenotypic intervention. 
The lack of data on the role of HCV infections acquired through high-risk practices abroad 
could limit the accuracy of our predictions. While a phylogenetic study provided evidence for 
dominant domestic transmission in Switzerland (21), more detailed analyses to quantify the 
relative contributions of domestic and imported transmissions are needed to reach a 
conclusion on this matter. Nevertheless, a sensitivity analysis suggested that our results are 
robust to high fractions of infections due to contacts outside the modelled population. Of note, 
the Swiss-HCVree-trial collects data on the presumed place of HCV acquisition and we aim at 
performing phylogenetic studies to address this open question.  
The model assumed that HCV treatment with DAAs lasted for 12 weeks for all patients. In 
reality grazoprevir/elbasvir treatment is recommended to last for 16 weeks in patients with 
pre-existing NS5A resistance associated substitutions and in some treatment experienced 
patients (22). However, less than 10% of all study participants are expected to fulfil these 
criteria.  
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Our model neglects factors other than differential treatment rates across genotypes that could 
influence genotypes distribution (e.g., changes in demographics due to migrations). Therefore 
we implicitly assumed the genotype distribution to be static in scenarios without the Swiss-
HCVree-trial. 
Finally, because model parameterization only considered data collected before the recruitment 
period of the Swiss-HCVree-trial, recent changes in population characteristics may have been 
neglected. 
 
Outlook 
We aim to assess the accuracy of our model projections by comparing them with the real end-
of-study effects of the Swiss-HCVree-trial. The core transmission model is largely based on 
data from the SHCS and was shown to reproduce the epidemic accurately(7). However, 
comparing model outcomes with real data will help evaluate and improve the extent to which 
the model structure and underlying assumptions capture the key aspects of the dynamics of 
sexually transmitted HCV and its response to specific interventions. 
 
Implications of findings 
Our model projections suggest that a 1-year intensive intervention could save HCV treatment 
costs while boosting the benefits of long-term efforts to prevent high-risk behaviour and to 
increase treatment rate in clinical-routine. However, if treatment reimbursement restrictions 
are not relieved and the level of high-risk behaviour in the overall HIV-positive MSM 
population does not decrease, HCV-prevalence may double by 2025 despite intensive 
interventions. 
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The results of this study triggered the prolongation of the Swiss HCVree trial. Treatment for 
patients with reinfection with HCV genotypes 1 and 4 will be provided between March 2017 
and January 2018. 
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Table 1. Model parameters associated with the simulated scenarios 
Parameter Value Rationale 
Inside intensive-interventions    
treatment duration (weeks) 12 Standard duration
Time from recruitment to HCV treatment (moths)    
Pangenotypic intervention 3 Optimistic assumption
Swiss HCVree trial 9 As scheduled
Effectiveness of risk counselling interventions*   
Assumption   Main analyses 50%
   Sensitivity analysis III 75%
Outside intensive interventions     
Treatment duration (weeks) 12 Standard duration
Time from HCV infection to treatment in clinical-routine 
(years) [1-16.9] Assumption
Fraction with high-risk behaviour in the overall MSM 
population   
   Main analyses   
Stable at 2016 estimate 0.14** Assumption
50% reduction (in 2025) 0.07  
   Sensitivity analysis I   
50% increase (in 2025) 0.21  
Percentage of imported infections***  
Assumption   Main analyses 4%
   Sensitivity analysis II 25%
*% of patients with high-risk behaviour at enrolment who permanently stop this behaviour; ** 
Estimated within the model by using the rate of transition to unsafe sex and the proportion of 
patients with high-risk behaviour at time of HIV infection reported in (7); ***% of all HCV 
infections that occurred between 2000 and 2013 among MSM enrolled in HIV-care 
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Supplementary text figures and tables can be found in the Web Appendix 
 
Figure legends 
Figure 1. Scheme of the introduction of an intensive intervention.  
Simplified representation of the distribution of HIV-positive MSM when an intensive 
intervention is introduced. The size of the modules do not reflect the actual relative sizes of 
the subpopulations. 
 
Figure 2. End-of-intervention HCV prevalence projections. 
Without intensive-intervention (red and orange bars) and with the pangenotypic intervention 
(blue bars) assuming stable and reduced high-risk behaviour in the overall HIV-positive MSM 
population.  
The dashed rectangle highlights a common reimbursement restriction. 
 
Figure 3. A) Long-term HCV prevalence, B)  Cumulative treatment episodes and C) 
Percentage of treatment episodes averted between 2016 and 2025 by introducing the  
pangenotypic intervention. 
Without intensive-intervention (red and orange bars) and with the pangenotypic intervention 
(blue bars) assuming stable and reduced high-risk behaviour in the overall HIV-positive MSM 
population. Overall risk behaviour refers to high-risk behaviour among HIV-positive MSM. 
The dashed rectangle highlights a common reimbursement restriction. 
A
cc
ep
te
d 
A
rt
ic
le
Figure 4. Projected trajectories of H
distribution between 2016 and 2025
Assuming stable (left panels) and redu
HIV-positive MSM population. Projec
infection to treatment of 16.9 (F2 scen
 
 
  
CV A&B) prevalence and C&D) genotype 
 with and without the Swiss-HCVree-trial. 
ced (right panels) high-risk behaviour in the over
tions assumed standard-of-care mean time from H
ario) and 2 years. 
all 
CV 
 
A
cc
ep
te
d 
A
rt
ic
le
  
 
A
cc
ep
te
d 
A
rt
ic
le
  
 
A
cc
ep
te
d 
A
rt
ic
le
 
